End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
90.5 SAR | -1.09% | -5.53% | +2.49% |
04-04 | Middle East Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-31 | Middle East Healthcare Co. Reports Higher FY23 Profit, Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 32.23 and 23.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.55 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.49% | 2.22B | - | ||
-17.07% | 16.85B | B+ | ||
+3.60% | 12.34B | B | ||
+5.64% | 11.77B | B+ | ||
+5.16% | 10.28B | B+ | ||
+25.36% | 8.38B | B | ||
-0.68% | 7.88B | A- | ||
+22.18% | 7.29B | D | ||
+5.77% | 6.75B | B- | ||
+52.00% | 4.69B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4009 Stock
- Ratings Middle East Healthcare Company